Ovarian cancer is one of the most threatening malignant tumors in females due to the frequent occurrence of metastasis that precedes diagnosis. The present study explored the possibility of preventing ovarian cancer metastasis by promoting nm23H1 expression through adeno-associated virus (AAV)-mediated gene transfer. A cell line of high metastatic potential, SW626-M4, was derived by in vivo selection and used to establish an ovarian cancer metastasis model in the mouse. Liver metastasis and animal survival time were measured after transfer of a recombinant adeno-associated viral vector expressing nm23H1 (AAV-nm23H1) into the aforementioned model. Intraperitoneal injection of AAV-nm23H1 into this orthotopic implantation model of ovarian cancer resulted in (1) expression of the exogenous gene in more than 95% of tumor cells in situ in nude mice; (2) a 60% reduction in the number of animals developing liver metastases; and (3) a 35-day prolongation of median survival time compared with the untreated host group. In conclusion, the results support the feasibility of induction of nm23H1 expression through gene transfer as a therapeutic strategy for preventing metastases and prolonging host survival time, and indicate that AAV vectors deserve attention in the design of future gene therapy approaches to achieving long-term expression of curative genes in vivo.
Introduction
Ovarian cancer remains the most common cause of death from gynecological malignancy, and the fourth leading cause of cancer death in the female population after breast cancer, lung cancer, and colon cancer. As a result of the lack of effective screening strategies and the possible absence of symptoms with early-stage disease, 70% of the patients present with advanced disease including liver metastasis, when diagnosed. Furthermore, advances in surgical techniques and conventional chemotherapy have not had significant impact on the survival of ovarian cancer patients for three decades 1 and the longterm survival of patients with advanced disease does not exceed 30%. In view of this situation, more effective treatment strategies need to be developed for this deadly disease.
The acquisition of metastatic ability requires the coordinated expression of metastasis-promoting genes and the downregulation of metastasis-suppressing genes. In recent years, a number of metastasis-suppressor genes have been identified in various organ systems. [2] [3] [4] [5] [6] [7] [8] The nm23 gene, 9 which was isolated as a metastasis suppressor gene and belongs to a gene family that currently contains eight members, 10 exhibits metastasis-suppressor activity and has received particular attention. Human infiltrating ductal breast carcinomas with lymph node metastases contain quantitatively less nm23 mRNA than in tumors from patients without evidence of lymph node metastases. 11 In the case of human ovarian cancer, nm23 is related to the lymphatic dissemination of tumor cells and its expression has been suggested to be an independent prognostic factor. 2, 12, 13 Several experiments have shown that the exogenous expression of human nm23H1 results in a significant reduction of metastatic potential in vivo and impairment of cell migration ability in response to several cytokines in vitro. 2, 8, 13 Transfection of nm23 cDNA into metastatically competent breast carcinoma, 2, 12, 13 melanoma, 7, [14] [15] [16] colon carcinoma, 17 and oral squamous cell carcinoma cell lines 18 resulted in 40-98% decreased metastatic potential in vivo.
Gene-based therapy represents a novel investigational approach to the treatment of ovarian cancer. Initial gene therapy approaches for ovarian carcinoma used recombinant retrovirus-mediated transfer systems. [19] [20] [21] Recombinant adenoviral vectors have also been used as alternative vectors for gene delivery to tumor cells. 22 Although a variety of systems have been developed to achieve transgene expression in ovarian cancer cells, there are few studies on adeno-associated viral (AAV) vectors. Recombinant AAV vectors are promising alternative gene delivery systems, which have advantageous features including a low likelihood of reversion to replication competency, high stability, long-term transgene expression, and likely nonpathogenicity due to the complete absence of wild-type viral genes in the vector. The vector system offers a number of attractive features for gene therapy and is becoming more clinically practical compared with the first generation of adenoviral vectors. [23] [24] [25] [26] Interestingly, these advances in AAV transduction in vivo have been directly facilitated by the ability to produce and purify vector particles. It is not surprising that given the cryptic nature of this virus, new insights into its biology have affected vector production schemes. Moreover, long-term AAV-mediated transgene expression has been demonstrated in several animal models of human disease. [25] [26] [27] [28] By contrast, first-generation adenoviral-mediated vectors displayed transient transgene expression and some vector-related toxicity. [25] [26] [27] [28] Recent advances in the production of high-titer purified AAV vector stocks have made the transition to human clinical trials a reality. 29 In the present study, we isolated SW626-M4, an ovarian carcinoma cell line with high metastatic potential, by in vivo selection. We then used it to establish an orthotopic implantation mouse model of ovarian cancer, and used AAV as a gene delivery vector to test the hypothesis that the metastatic potential of SW626-M4 in the host could be reversed by means of AAV-mediated nm23H1 gene transfer.
Materials and methods

Cell culture
Human ovarian adenocarcinoma cell lines SW626 and human embryonic kidney cell line 293 were obtained from American Type Culture Collection (ATCC). SW626 and its highly metastatic subline SW626-M were cultured in L-15 medium containing 10% heat-inactivated fetal calf serum, 4500 mg/l L-glutamine, 110 mg/l sodium pyruvate with nonessential amino acids, 1% HEPES buffer, 1 U/ml penicillin, and 100 mg/ml streptomycin. 293 cells were maintained in DMEM-F12 plus 10% FBS, and 2 mM glutamine. These cells were routinely cultured in a humidified incubator at 371C with 5% CO 2 .
Construction of the orthotopic implantation model SW626 cells were harvested by trypsinization, washed three times with cold serum-containing medium, kept on ice, and were injected in a total volume of 0.4 ml within 40 min of harvesting. Three 4-week-old BALB/C nu/nu female mice (purchased from Medical Department of Beijing University) were injected subcutaneously (s.c.) with a single dose of 10 6 tumor cells. The nude mice were killed to harvest the tumor fragments 3 weeks after tumor cell injection. Fresh tumor fragments (1 mm 3 ) were then implanted by surgical orthotopic implantation on the ovarian serosa in nude mice. The mice were anesthetized by ketamine hydrochloride (10 mg/kg) given intramuscularly. An incision was made through the left lower abdominal pararectal line and peritoneum. The left ovary was exposed, and part of the serosal membrane was scraped with forceps. Two 1-mm 3 tumor pieces were fixed on the scraped site of the serosal surface with a 5-0 absorbent suture. The ovary was then returned into the peritoneal cavity, and the abdominal wall and skin were closed with 3-0 sutures.
In vivo selection of metastatic variants from SW626 cell line The inguinal lymph node metastases were obtained aseptically after necropsy and dissociated mechanically using a wire mesh sieve, then cultured in selective medium consisting of a modification of MEM with the addition of cholera toxin (500 ng/ml), epidermal growth factor (EGF) (1 ng/ml), and 10% FBS. Cells were grown in this medium for two passages and then maintained in DMEM with 15% FBS. Cytogenetic analysis was used to confirm the human origin of the cells. The cell line was designated SW626-M1. SW626-M1 then was used to develop the orthotopic model of ovarian tumor. To do this, SW626-M1 cells were reinjected into the ovary to produce subsequent lymph node metastases, and SW626-M2 cells were isolated by the aforementioned method. After four passages, we developed a highly metastatic ovarian tumor cell line, which we named SW626-M4.
Recombinant ADENO-associated-virus-nm23H1 construction Full-length nm23H1 cDNA fragment was cut by XhoI and NheI from plasmid pcDNA3.1-nm23H1. The 1.1 kb cDNA fragment was subcloned into pBlueScript that had been cut with XhoI and XbaI, to give pBlueScriptnm23H1. The nm23H1 fragment was freed from the plasmid by NotI digestion, and then inserted into NotIdigested pXXUF 1 to produce pXXUF 1 -nm23H1. ADENOassociated-virus-nm23H1 (AAV-nm23H1) was generated by cotransfection of pXXUF 1 -nm23H1, PXX 2 , and PXX 6 into 293 cells. AAV-LacZ was produced using the same protocol by inserting the full-length b-galactosidase (LacZ) gene instead of nm23H1. Both viruses were characterized, propagated, and purified by CsCl density gradient centrifugation as described. 30 AAV virus titers were determined by quantitative DNA dot-blot hybridization as recommended. Western blot analysis of nm23H1 expression For Western blot analysis, cells were lysed by the addition of 20% SDS containing 1 mM phenylmethylsulfonyl nm23H1 and inhibition of ovarian cancer metastasis J Li et al fluoride (PMSF). The lysate was sonicated for 30 s on ice, followed by centrifugation at 13 000 g for 30 min at 41C. A 20 mg of total protein from each sample was separated on a 10% SDS-polyacrylamide gel and electrotransferred to a nitrocellulose membrane. After blocking with Tris-buffered saline/Tween-20 (TBST) containing 5% powdered milk, the membrane was incubated with antihuman nm23H1 monoclonal antibody (Santa Cruz Biotechnology, CA) overnight at 41C, followed by incubation with HRP-conjugated anti-mouse IgG (Santa Cruz Biotechnology, CA). After extensive washing, the protein was visualized with an enhanced chemiluminescence (ECL) detection kit (Pierce, IL). As an internal control, b-actin expression was detected using the same protocol, except that mouse anti-actin monoclonal IgG 1 (Santa Cruz Biotechnology, CA) was used as the primary antibody.
In vivo gene transfer with AAV vector
The highly metastatic subline SW626-M4 was used to establish the orthotopic implantation model, according to the method described above. On days 14 and 21 after transplantation of the tumor fragments, 1 Â 10 10 particles/ ml of AAV-nm23H1, or 1 Â 10 10 particles/ml of AAVLacZ in 500 ml PBS was intraperitoneally (i.p.) injected into recipient mice. Vehicle-treated mice (bearing the control tumors) received PBS alone in identical fashion. The effect of AAV-nm23H1 on survival and liver metastatic incident rates in the models were observed. For survival analysis, the mice were euthanized and killed when they appeared moribund (AAV-nm23H1 and AAVLacZ groups, n ¼ 13 for each; for the PBS group, n ¼ 12). For observation of liver metastases, three other groups of mice (AAV-nm23H1 and AAV-LacZ groups, n ¼ 13 each; PBS group, n ¼ 12) were euthanized on day 84 and liver metastases were evaluated histopathologically.
Histochemical analysis of nm23H1 expression in vivo For histochemical detection of nm23H1 expression in vivo, serial sections of the sample tissues were made. A murine lgG anti-human nm23H1 monoclonal antibody (Santa Cruz Biotechnology, CA) was used on paraffin-embedded tumor tissue, followed by an immunoperoxidase procedure. To eliminate the endogenous expression of nm23H1, exogenous gene expression mediated by AAV in vivo was also verified by b-galactosidase staining of frozen tumor sections from mice inoculated with AAV-LacZ in parallel. To do this, sections were fixed at room temperature in 0.5% glutaraldehyde (freshly prepared in PBS) for 15 min and washed extensively in PBS. b-Galactosidase activity was detected by immersing sections into 5-bromo-4-cholro-3-indoly1 b-galactopyranoside (X-Gal) staining solution (5 mM K 3 Fe[CN] 6 , 5mM K 4 Fe[CN] 6 , 2mM MgCl 2 , 1 mg/ml X-Gal) for 15 h at 371C.
Assessment of hepatic metastases
Liver metastases of ovarian tumor cells were detected by histopathologic examination when the mice were killed as described above. The severity of metastasis was scored as clear (0 ¼ no discernible foci), minimal involvement (1 þ ¼ metastatic tumors involving less than 10% of the liver), moderate (2 þ ¼ metastatic tumors involving 10% to 25% of the liver), or extensive (3 þ ¼ metastatic tumor mass involving X25% of the liver). Data were also reported as 'incidence of metastases', which is defined as the percentage of animals harboring one or more liver metastases.
Statistical analysis
The statistical significance of differences in survival times among groups was determined by using a Kaplan-Meier survival analysis, and Wilcoxon test. A value of Po0.05 was considered significant. Cox proportional hazards modeling of factors potentially related to survival was performed to identify independent factors that might jointly have a significant influence on survival.
Results
Construction and characterization of AAV vectors
Recombinant AAV vectors are promising alternative gene delivery systems, based on the defective and nonpathogenic parvovirus adeno-associated virus type 2 (AAV-2). We used this novel, helper virus-free packaging protocol, to efficiently produce AAV virions encoding LacZ and nm23H1. Two vectors based on the AAV serotype 2 were constructed, expressing human nm23H1 (AAV-nm23H1) or the LacZ gene (AAV-LacZ) under the control of the human cytomegalovirus (CMV) promoter. The correct construction of the vectors carrying the cDNA encoding nm23H1 was confirmed by restriction digestion and agarose gel electrophoresis (Figure 1a AAV-LacZ and AAV-nm23H1 were packaged and purified, resulting in high titers up to 1 Â 10 10 particles/ml (Figure 1b and c) .
Selection and characterization of metastatic variants of the SW626 line
To demonstrate that nm23H1 was important for tumor metastasis, we developed an orthotopic transplantation model to study this process in nude mice, using the human ovarian carcinoma cell line SW626. The host mice were euthanized on day 84 after implantation. In seven of 10 mice, we found SW626 tumors, and three of 10 mice had microscopic metastases in the inguinal glands. The highly metastatic subline SW626-M4 were selected in nude mice by four circles of repeated orthotopic transplantation, lymph node metastasis formation, and in vitro culture of the tumor cells. After four passages, B-ultrasound on day 14 after implantation revealed SW626 tumors in all mice hosting SW626-M4 cells, and metastases were found in 65-70% of inguinal glands on day 84 after implantation, by anatomical evaluation. Furthermore, Western blot analysis revealed that the expression of nm23H1 in SW626-M4 cells was significantly lower than in the parent SW626 line (Figure 2) . Thus, the SW626-M4 cells from host mice were highly tumorigenic and had high metastatic potential. These data suggested that low nm23H1 gene expression correlates closely with highly productive tumor metastasis.
In vitro and in vivo gene transfer mediated by AAV We detected AAV-mediated exogenous nm23H1 expression by Western blotting. Nm23H1 expression was substantially increased in SW626-M4 cells transfected in vitro with AAV-nm23H1 compared with parent SW626 cells and SW626-M4 cells transfected with AAV-LacZ (Figure 2 ).
To confirm that gene transfer could be achieved in the ovarian tumor, recombinant AAV containing the nm23H1 gene was i.p. inoculated into nude mice that had received orthotopic ovarian cancer transplants. The efficacy of AAV-nm23H1-mediated transduction was examined on day 84 after tumor transplantation. Successful gene transfer and expression of the nm23H1 gene product were confirmed by immunohistological analysis of the ovarian cancer, and revealed that 495% of the ovarian tumor cells were stained strongly with a monoclonal antibody directed against nm23H1 (Figure 3a) . In contrast, slight positive staining of nm23H1, representing its endogenous expression, was observed in ovarian cancer treated with the AAV-LacZ reporter gene vector (Figure 3b ). For b-galactosidase staining, about 90% of cells has detectable b-galactosidase activity in vivo (data not shown), which was consistent with the AAV-nm23H1 result.
Efficacy of i.p. gene transfer in inhibiting ovarian tumor metastasis
The effect of AAV-nm23H1 gene transfer in preventing the metastasis of human ovarian tumor cells (SW626-M4) nm23H1 and inhibition of ovarian cancer metastasis J Li et al was evaluated by recording the incidence of liver metastases and host survival time. As shown in Table 1 , 75% of the PBS-treated control host mice bearing SW626-M4 tumor cells produced discernible liver metastases by day 84 postimplantation. The number of metastases in the group inoculated with AAV-LacZ was slightly lower, but this difference was not statistically significant. However, sharp, statistically significant reductions in both the severity and frequency of liver metastases were seen in the host mice that received AAV-nm23H1. The data showed a 60% reduction in the number of animals developing liver metastases in the AAV-nm23H1-treated group compared with the PBS-treated group (Table 1) .
As shown in the Kaplan-Meier survival curve (Figure 4 ), there were no significant differences in animal survival between the untreated animals and the group treated with AAV-LacZ. In contrast, the animals treated with AAV-nm23H1 showed a markedly prolonged survival time (median time-to-death 35 days longer than that of the PBS-treated animals, Po0.05). This experiment indicates that AAV-nm23H1 can reverse ovarian tumor metastasis in an orthotopic implantation model, and thus lengthen the survival time of the treated animals.
Discussion
Gene delivery to ovarian cancer cells may allow new therapeutic approaches to this life-threatening disease. Thus far, this goal has been successfully achieved with adenoviral vectors that have been widely used both in preclinical models 29, 30 and in clinical trials to deliver HSV-TK in ovarian cancer patients. 31, 32 Using adenoviral vectors, transduction efficiency is generally high, yet their clinical use might be limited by possible vector-related toxicity, short-term expression of the transgene due to nonintegration of the therapeutic gene into the DNA of the tumor cell, and clearance of transduced cells by the immune response. Previous studies have demonstrated that a single peroral administration of the AAV vector resulted in persistent expression of a transgene and longlasting phenotypic correction in a rat model for more than six months. 32, 33 In the present study, we used a novel AAV packaging system based on pXX2 and pXX6. These two new plasmids can increase AAV vector yields 40-fold, and are completely free of Ad. 29, 30, 34 We first constructed high titer, pure viral preparations of AAV-nm23H1, with which we achieved gene transfer into 95% of ovarian tumor cells in vivo, suggesting that it is an extremely suitable tool for clinical experiments using AAV.
Lymph node metastasis through the lymphatic vessels is a critical step in determining the outcome of ovarian cancer patients, and prognosis should be improved by preventing lymph node metastasis. Clinically relevant animal models of human cancer are important for studies of cancer biology, invasion, and metastasis, and for investigating new methods of prognostic diagnosis and therapy identification. 33, 35, 36 Experimental models of metastasis of ovarian carcinoma to the lymph node are not available. In the present study, we developed a highly metastatic orthotopic transplantation model of ovarian cancer using SW626-M4, a cell subline of high metastatic potential and low nm23H1 expression, to mimic the natural history of highly metastatic ovarian cancer in humans. This model seems to correspond to the advanced clinical stage of ovarian carcinomas, and it should be useful in understanding the molecular biology of ovarian carcinomas and in the development of therapies. Unlike previous studies that used in vitro nm23H1 gene transfer, this study employed in vivo gene transfer into pre-existing primary tumors, and thus represents a clinically relevant model with which we explored the feasibility of using AAV-nm23H1 to inhibit metastasis.
Although a number of biological molecules related to metastasis in ovarian tumors have been elucidated, 37 the precise role of nm23H1 in limiting metastasis is undefined. Recent studies have demonstrated that the nm23H1 gene plays a major role in metastasis and its mechanism of suppressing metastasis may involve downregulation of nm23H1 and inhibition of ovarian cancer metastasis J Li et al genes associated with cell adhesion and motility (integrins alpha2, -8, -9, -L, and -V, collagen type VIII alpha1, fibronectin 1, catenin, TGF-beta2, FGF7, MMP14 and 16, ErbB2), and possibly certain tumor/metastasis suppressors (two members of SWI/SNF-related matrix-associated proteins 2 and 5, and PTEN). 2, 8, 38 Moreover, nm23H1 may negatively regulate Tiam1 and inhibit Rac1 activation in vivo. Its regulation of Rac1 implicated nm23H1 in the suppression of tumor metastasis. Our results also showed that poor nm23H1 expression is correlated with high metastatic potential, extending the role of nm23H1 as a metastatic suppressor gene to ovarian cancer. Suzuki et al. 39 found that nm23H1 strongly inhibited the liver metastasis of HT-29 cells in nude mice and inhibited EGF-induced cell migration in vitro after nm23H1 cDNA transfection. In a similar study, Khan et al. 40 reported that nm23H1-transfected HSC3 cell lines showed a significant reduction in cell motility in a dose-dependent manner, and were noninvasive. The present study extends these observations and supports the feasibility of gene transfer in a clinically relevant setting. The results demonstrate the extraordinary in situ transduction efficiency of AAV-nm23H1, as more than 95% of the ovarian cancer cells expressed the transgene after i.p. gene transfer. It is clear that a high efficiency of intratumoral gene transfer can be accomplished in situ with only one or two injections of AAV vector.
One of the utmost goals of cancer gene therapy is to decrease the possibility of metastasis, and then to prevent tumor recrudescence, so every possible route to this end should be tried. The i.p. injection is an easy way to deliver chemical drugs to the abdominal cavity and has been used in routine ovarian cancer chemotherapy and in adenovirus-based gene therapy. 31 To explore its usefulness in AAV-mediated gene therapy, AAV-nm23H1 virions were i.p. injected into nude mice bearing human ovarian tumor implants. Results from the experiments suggest that this route offers a less traumatic and perhaps an efficient method for targeted gene therapy. i.p. injection of AAVnm23H1 resulted in significant reductions in the incidence and severity of metastatic liver lesions. It revealed that the AAV vector has a predilection for transducing cells of the liver, 41 which appears to be the target organ most commonly affected by ovarian cancer metastases. More importantly, hosts treated via i.p. gene transfer survived significantly longer than untreated controls and controls treated with the AAV-LacZ vector. These results suggest that gene transfer can significantly prolong host survival, the most critical parameter for gauging therapeutic success in tumor-bearing hosts. Therefore, AAVnm23H1 may be an ideal tool to prevent or inhibit metastasis of ovarian tumor cells from primary sites, and deserves extensive study.
